Can-Fite BioPharma (NYSE:CANF) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF – Get Rating) in a research report released on Friday morning. The firm issued a sell rating on the stock.

Shares of CANF opened at $0.87 on Friday. Can-Fite BioPharma has a fifty-two week low of $0.78 and a fifty-two week high of $2.62.

Can-Fite BioPharma Company Profile (Get Rating)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.

Further Reading